# Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride

> **NCT03333265** · PHASE2,PHASE3 · COMPLETED · sponsor: **Xijing Hospital of Digestive Diseases** · enrollment: 100 (actual)

## Conditions studied

- Colorectal Adenomas

## Interventions

- **DRUG:** 100mg Berberine hydrochloride
- **DRUG:** 300mg Berberine hydrochloride
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03333265
- **Lead sponsor:** Xijing Hospital of Digestive Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-01
- **Primary completion:** 2020-08-31
- **Final completion:** 2021-06-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03333265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03333265, "Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03333265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*